Healthcare
Heron Therapeutics, Inc.(HRTX)
Live Price
Offline$0.42
+7.69% today
1Y Change
-80.47%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $190.00M
- Revenue Growth
- +7.4%
- EPS Growth
- -34.7%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Heron Therapeutics, Inc. (HRTX) is a Healthcare stock with a market cap of $190.00M and listed on NASDAQ. The stock last traded around $0.42 and down 80.5% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +7.4%, EPS growth of -34.7%, a dividend yield of 0.0%. What stands out right now is revenue +7.4%, EPS -34.7%, free cash flow -15.2% with operating margin -1.6% and ROIC -1.6%. Valuation is more restrained than many high-expectation growth names at price/sales 1.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines HRTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+7.4% vs +7.6% peer median
Operating Margin
Below sector median
-1.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +7.4% and EPS is at -34.7%, with operating margin around -1.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -11.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +6.5% | -22.0% | -63.4% |
2026 Feb 26, 2026 | +33.3% | -0.8% | -15.0% | -30.8% |
2025 Nov 4, 2025 | -275.1% | -2.6% | +1.8% | +11.4% |
Benchmark Edge
HRTX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HRTX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HRTX Max Drawdown
-82.96%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HRTX and SPY.
Company Overview
Heron Therapeutics, Inc.
NASDAQ Capital Market
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
- Leadership
- Craig Alexander Collard
- IPO Date
- Aug 26, 1987
- Employees
- 122
- Street Address
- 4242 Campus Point Court
- Mailing
- Cary, CA, 92121
- Region
- Cary, CA, US
- Reporting Currency
- USD
- Investor Line
- 858 251 4400
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.2
- Price/Book
- 14.0
Growth
- Revenue
- +7.4%
- EPS
- -34.7%
- Free Cash Flow
- -15.2%
Profitability
- Gross Margin
- 73.3%
- Operating Margin
- -1.6%
- Net Margin
- -13.0%
- ROE
- 304.9%
- ROIC
- -1.6%
Balance Sheet
- Debt/Equity
- 9.81
- Current Ratio
- 2.48
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.